Patients with long-standing type 2 diabetes mellitus (T2DM) can be clinically challenging for physicians to treat because these patients often lack sufficient β-cell function to respond to some oral glucose-lowering agents, may have profound comorbidities, and may have renal impairment that limits the use of traditional agents. These complications, in addition to older age, also increase the risk of hypoglycemia, which can be a major barrier to treatment success. Individualizing treatment targets to balance the benefits of glycemic control with risks of hypoglycemia is the first step to successfully treating these 
have uncertain benefit. 4 The concept of higher (or lower) glucose targets, depending on individual patient characteristics, was first widely embraced because of these uncertain benefits. 5 The risk of severe hypoglycemia likely represents the greatest barrier to T2DM care in older patients and in those with diabetes of long duration. showed the natural progression of
Patient Management
A decision has been made to start a patient on insulin because they are not achieving their targets.
Basal insulin analogs have proven efficacy, once-daily dosing, and lower risk of hypoglycemia than alternative insulin therapies.
Pen devices for insulin delivery are convenient, painless, and discreet.
Patient Discussion: Insulin Initiation and Adjustment Recommendations
Invite the patient to bring a family member or friend for support.
Show the patient how to use the pen device (needle placement, dialing insulin, discharging dose).
Ask the patient to self-inject a token amount of insulin (1-2 units) during an appointment.
Discuss initial insulin dose, timing (dinner, bedtime, or morning) and dose adjustments including ditration algorithm, based on agreed upon blood glucose targets.
Review importance of glucose selfmonitoring for insulin self-titration.
Suggest using a diary to record insulin dose and daily glucose levels.
Resolve any concerns before the patient leaves.
Arrange a follow-up after 1 week (visit or phone) to review and adjust therapy. (Figure 3) . [32] [33] [34] In the Sitagliptin Saxagliptin Linagliptin Alogliptin Alogliptin study 33 study 34 study 32 study, 12.5 mg 35 should not be used in these patients.
decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased in a large group of patients with T2DM who had a history of, or were at risk for, cardiovascular events. 38 The Renal impairment is another important issue that increases hypoglycemia risk and is more prevalent in older patients. 6 Metformin is not recom- Glucagon-like peptide-1 receptor agonists, given by subcutaneous injection, offer more robust glucose lowering, a low risk of hypoglycemia, and the possibility of lower insulin needs and weight loss.
